TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. We retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.
San Diego, US
Size (employees)
26 (est)+19%
TRACON Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
700 8910 University Center Ln

TRACON Pharmaceuticals Metrics

TRACON Pharmaceuticals Financial Metrics

Net income (2016)

($27 m)

Market capitalization (28-Apr-2017)

$55.8 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$35.7 m
TRACON Pharmaceuticals's current market capitalization is $55.8 m.
FY, 2015FY, 2016

R&D expense

$25.7 m$21.6 m

General and administrative expense

$5.7 m$7.9 m

Operating expense total

$31.4 m$29.4 m


($23.5 m)($26 m)

Interest expense

($923 k)($1.1 m)

Net Income

($24.4 m)($27 m)
FY, 2015FY, 2016


$41.4 m$35.7 m

Accounts Receivable

$9.4 m


$8 m

Current Assets

$53.3 m$45.6 m


$173 k$82 k

Total Assets

$53.5 m$45.7 m

Accounts Payable

$28.7 m

Current Liabilities

$14.2 m$10.2 m

Additional Paid-in Capital

$89.6 m$113.9 m

Retained Earnings

($58.6 m)($85.6 m)

Total Equity

$31 m$28.3 m

Financial Leverage

1.7 x1.6 x
FY, 2015FY, 2016

Net Income

($24.4 m)($27 m)

Depreciation and Amortization

$94 k

Cash From Operating Activities

($27.2 m)

Purchases of PP&E

($3 k)

Cash From Investing Activities

$2.1 m

Long-term Borrowings

($2 m)

Cash From Financing Activities

$19.4 m

Interest Paid

$622 k

TRACON Pharmaceuticals Market Value History

TRACON Pharmaceuticals Company Life

You may also be interested in